REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming virtual investor conferences. The Barclays Gene Editing & Gene Therapy Summit is set for November 15, 2021, at 1:30 p.m. ET. Additionally, the Piper Sandler 33rd Annual Virtual Healthcare Conference will take place on December 2, 2021, with a recorded fireside chat available starting November 22, 2021, at 10:00 a.m. ET. A live webcast and recorded presentations can be accessed via REGENXBIO's website for 30 days post-event.

ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format:

Barclays Gene Editing & Gene Therapy Summit
Presentation: Monday, November 15, 2021, at 1:30 p.m. ET

Piper Sandler 33rd Annual Virtual Healthcare Conference
Date: December 2, 2021
Recorded Fireside Chat will be available: Monday, November 22, 2021, at 10:00 a.m. ET

A live webcast of the Barclays presentation and the recording of the Piper Sandler fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com for approximately 30 days following the events.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV^® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301418127.html

SOURCE REGENXBIO Inc.

FAQ

What is the date and time of REGENXBIO's presentation at the Barclays Summit?

REGENXBIO's presentation at the Barclays Gene Editing & Gene Therapy Summit is scheduled for November 15, 2021, at 1:30 p.m. ET.

When will the recorded fireside chat from the Piper Sandler Conference be available?

The recorded fireside chat from the Piper Sandler 33rd Annual Virtual Healthcare Conference will be available starting November 22, 2021, at 10:00 a.m. ET.

How can I access the live webcasts for REGENXBIO's conferences?

You can access the live webcasts and recorded presentations on REGENXBIO's website in the Investors section for approximately 30 days after the events.

What is the focus of REGENXBIO Inc.?

REGENXBIO is focused on improving lives through gene therapy, utilizing its NAV Technology Platform for developing candidates across various therapeutic areas.

What technology does REGENXBIO use for gene delivery?

REGENXBIO uses its proprietary NAV Technology Platform, which includes exclusive rights to over 100 novel adeno-associated virus (AAV) vectors.